| Trial ID: | L4310 | 
                      | Source ID: | NCT02354235 | 
                      | Associated Drug: | Teneligliptin | 
                      | Title: | Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin) | 
                      | Acronym: |  | 
                      | Status: | COMPLETED | 
                      | Study Results: | YES | 
                      | Results: | https://ClinicalTrials.gov/show/NCT02354235/results | 
                      | Conditions: | Type 2 Diabetes Mellitus | 
                      | Interventions: | DRUG: Teneligliptin|DRUG: Canagliflozin|DRUG: Placebo | 
                      | Outcome Measures: | Primary: Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c), The change from baseline in percentage of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 24., Baseline, 24 Weeks | Secondary: Change From Baseline in Fasting Plasma Glucose Level, The change from baseline in fasting plasma glucose level collected at Week 24., Baseline, 24 Weeks|Percentage Change in Body Weight From Baseline, The percentage change from baseline in body weight collected at Week 24., Baseline, 24 Weeks|Change From Baseline in the AUC(0-2h) for Postprandial Plasma Glucose (PPG), The change from Baseline in AUC(0-2h) for Postprandial Plasma Glucose collected at Week 24., 0, 0.5, 1 and 2 hour postprandial, at Baseline and 24 Weeks|Change From Baseline in 2-hour Postprandial Plasma Glucose Level, The change from baseline in 2-hour postprandial plasma glucose level collected at Week 24., 2 Hours Postprandial, at Baseline and 24 Weeks | 
                      | Sponsor/Collaborators: | Sponsor: Mitsubishi Tanabe Pharma Corporation | 
                      | Gender: | ALL | 
                      | Age: | ADULT, OLDER_ADULT | 
                      | Phases: | PHASE3 | 
                      | Enrollment: | 138 | 
                      | Study Type: | INTERVENTIONAL | 
                      | Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | 
                      | Start Date: | 2015-01 | 
                      | Completion Date: | 2016-01 | 
                      | Results First Posted: | 2018-08-16 | 
                      | Last Update Posted: | 2018-11-01 | 
                      | Locations: | Reserch site, Kanto, Japan|Reserch site, Kinki, Japan|Reserch site, Tohoku, Japan | 
                      | URL: | https://clinicaltrials.gov/show/NCT02354235 |